Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novo Nordisk submits diabetes pill for U.S. approval

Novo Nordisk submitted the company’s oral semaglutide drug, a pill that management hopes will transform the diabetes market, for approval in the United States.

Read More »

Novo Nordisk’s Ozempic Continues to Show Superiority in Diabetes Control

Novo Nordisk announced the results from a Phase IIIb trial comparing Ozempic (semaglutide) with an SGLT-2 inhibitor or placebo in adults with type 2 diabetes.

Read More »

MIT Develops Micro-Injection Pill for Oral Insulin

A research team at Massachusetts Institute of Technology (MIT) developed a capsule about the size of a blueberry that holds a tiny needle that, after being swallowed, injects insulin into the stomach.

Read More »

U.S. lawmakers request info from insulin makers on rising prices

Two powerful U.S. lawmakers sent letters to the three leading insulin manufacturers requesting information on why its cost has skyrocketed in recent years and how much the companies profit from the life-sustaining diabetes treatment.

Read More »

Cost keeps many diabetics from taking needed insulin

The cost of insulin prevents many people with diabetes from taking it as directed, a small survey suggests.

Read More »

AstraZeneca’s Farxiga curbs heart failure, kidney risks

The largest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca’s Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients.

Read More »

Eli Lilly’s diabetes treatment meets main goal in two late-stage studies

Eli Lilly and Co.’s experimental diabetes treatment Ultra Rapid Lispro was shown to be as effective as the drugmaker’s blockbuster Humalog medicine in two late-stage studies.

Read More »

Novo Nordisk’s Semaglutide Hits Mark in T2D Trial

Novo Nordisk revealed that oral semaglutide achieved positive results in the PIONEER 5 study for the reduction of blood sugar levels and weight in adults with type 2 diabetes.

Read More »

Highmark inks outcomes contract with second pharma brand

Continuing its efforts to address high prescription drug costs, insurer Highmark entered into a new outcomes-based contract with Boehringer Ingelheim for Jardiance (empagliflozin), an oral medicine indicated to lower blood sugar in adults with type 2 diabetes, and also to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease.

Read More »

Janssen Halts Phase III Kidney Disease Trial Early After Endpoints Were Met

Janssen Pharmaceuticals halted the company’s Phase III chronic kidney disease trial for Invokana early due to the fact that the SGLT2 diabetes drug had already achieved pre-specified efficacy data.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom